

PATENT  
Attorney Docket No.: 15270J004740  
Client Reference No.: 00-209-US-CIP5

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Schenk, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

RESPONSE

#18  
J.S.J.  
4/7/01

**FAX RECEIVED**  
**APR 06 2001**  
**GROUP 1600**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This paper is filed in response to the Notice to Comply With Requirements For Patent Applications Containing Sequence Disclosures mailed March 5, 2001. In response to the Notice to Comply With Requirements For Patent Applications Containing Sequence Disclosures Action mailed September 29, 2000, Applicant filed a Communication Under 37 C.F.R. §§ 1.821-1.825 and Amendment, a copy of which is attached. The Communication and Amendment were deposited with the United States Postal Service on December 13, 2000 under 37 C.F.R. § 1.8. A Petition to Extend Time, attached, was also filed on December 13, 2000. Applicant believes that the Communication filed on December 13, 2000 is responsive to the Notice mailed March 5, 2000.

After reviewing the PAIR File Contents History Information, it appears the CRF was received, found to be technically good, and entered into the database. However, it is unclear if the Amendment filed December 13, 2000 has been entered in the above-identified matter. If the Amendment has not been entered, Applicant requests its entry in adherence with 37 C.F.R. §§ 1.821-1.825. If the Amendment was entered, Applicant requests the Examiner provide further guidance regarding the alleged failure to comply with 37 C.F.R. §§ 1.821-1.825.

If the Examiner believes a telephone conference would expedite prosecution of this application, please contact the undersigned attorney at 650-326-2400.

PATENT

Schenk, Dale B.  
Application No.: 09/322,289  
Page 2

Respectfully submitted,

*Rosemarie L. Celli*

Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
RLC  
PA 3138097 v1

PTO FAX NO.: 1-703-308-4242

ATTENTION: Examiner Turner  
Group Art Unit 1647

In re Application of:  
Schenk, D.,  
Application No.: 09/322,289  
Filed: May 28, 1999  
For: Prevention And Treatment Of Amyloidogenic Disease

Atty Docket No.: 15270J004740  
Client Ref. No.: 00209-US-CIP5

FAX RECEIVED  
APR 06 2001  
GROUP 1600

**OFFICIAL COMMUNICATION  
FOR THE PERSONAL ATTENTION OF  
EXAMINER TURNER**


**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that the following correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. 1-703-308-4242 on April 5, 2001:

Response (2 pages); Communication Under 37 C.F.R. §§ 1.821-1.825 and Amendment mailed December 13, 2000; Petition to Extend Time mailed December 13, 2000; and Appointment of Associate Attorney Under 37 CFR § 1.34(b) (2 pages).

Number of pages being transmitted, including this page: 8 (eight)

Dated: April 5, 2001

  
Rosemarie L. Celli  
Reg. No. 42,397

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT 650-326-2422**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
Telephone: (415) 576-0200  
Fax: (415) 576-0300

APR. 5. 2001 6:44AM TOWNSEND & TOWNSEND  
I hereby certify that this communication is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

NO. 862 P. 4/8 NT  
Attorney Docket No.: 15270J-004740US

Assistant Commissioner for Patents  
Attn: Box Missing Parts  
Washington, D.C. 20231

On December 13, 2000  
TOWNSEND and TOWNSEND and CREW LLP  
*Paula Faulk Shirley*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

SCHENK, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

**COMMUNICATION UNDER**

**37 C.F.R. §§ 1.821-1.825**

**AND**

**AMENDMENT**

**Box SEQUENCE**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed September 29, 2000, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

**IN THE SPECIFICATION:**

On page 11, line 25, insert --(SEQ ID NO:1)-- after "-Ala-OH".

On page 50, line 11, replace "NH<sub>2</sub>-DAEFRHDSGYEVC-COOH" with  
--NH<sub>2</sub>-DAEFRHDSGYEVS-COOH (SEQ ID NO:2)--

On page 50, line 12, replace "NH<sub>2</sub>-DAEFRG-COOH" with  
--NH<sub>2</sub>-DAEFRG-COOH (SEQ ID NO:3)--

On page 50, line 13, replace  
"NH<sub>2</sub>-C-amino-heptanoic acid-GLMVGGVVIA-COOH" with  
-NH<sub>2</sub>-C-amino-heptanoic acid-GLMVGGVVIA-COOH (SEQ ID NO:4)-.

On page 50, line 14, replace "Ac-NH-HHQLVFFAEDVGSNKGGC-COOH"  
with --Ac-NH-HHQLVFFAEDVGSNKGGC-COOH (SEQ ID NO:5)-.

On page 83, line 32, replace "APP- $\delta$ /FL" with -APP- $\alpha$ /FL-.

Please insert the accompanying paper copy of the Sequence Listing, page  
numbers 1 and 2, at the end of the application.


#### REMARKS

Applicants request entry of this amendment in adherence with 37 C.F.R.  
§§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above  
named sequences, SEQ ID NOS:1-5, in computer readable form, and a paper copy of the  
sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through  
the use of the software program "PatentIn" and is identical to that of the paper copy. This  
amendment contains no new matter.

If the Examiner believes a telephone conference would expedite prosecution of  
this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Joe Liebeschuetz  
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (650) 326-2400  
Fax: (650) 326-2422  
JOL:dmw  
SF 1162971 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

**PATENT**  
Attorney Docket No.: 15270J-004740US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On December 13, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: Paula Sue Shirley

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

SCHENK, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

PETITION TO EXTEND TIME

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicant petitions the Assistant Commissioner of Patents to extend the time for response to the Restriction Requirement dated September 29, 2000 for 2 months, from October 29, 2000 to December 29, 2000. An appropriate response in the form of a Response to Restriction Requirement is enclosed herewith.

Please charge the fee of \$390.00 to the undersigned's Deposit Account No. 20-1430. Please charge any additional fees or credit overpayment to the above deposit account. This petition is submitted in triplicate.

Respectfully submitted,

Joe Liebeschuetz  
Joe Liebeschuetz  
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
JOL:pfb PA 3116139 v1

PATENT  
 Attorney Docket No.: 15270J004740  
 Client Reference No.: 00-209-US-CIP5

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Schenk, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT  
 OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

APPOINTMENT OF ASSOCIATE  
 ATTORNEY UNDER 37 CFR § 1.34(b)

Assistant Commissioner for Patents  
 Washington, D.C. 20231

Sir:

Please recognize the following attorneys:

Nina Ashton, Reg. No. 37,273

Jean Duval, Reg. No. 32,731

Lisabeth Murphy, Reg. No. 31,547

whose address is 800 Gateway Boulevard, South San Francisco, CA 94080; and,

Rosemarie L. Celli, Reg. No. 42,397

whose address is Two Embarcadero Center, 8th Floor, San Francisco, California 94111-3834;  
 as my associates in the above-identified patent application to inspect the file, to prepare and  
 file amendments, to inspect and make copies thereof and of any papers in any appellate or *inter  
 partes* proceedings in which the application may be or become involved, and generally to  
 conduct all business in the United States Patent and Trademark Office relating to the  
 prosecution of the application or any application that claims priority from this application  
 provided that if any one of said attorneys ceases being affiliated with the law firm of Townsend  
 and Townsend and Crew as partner, employee or of counsel, such attorney's appointment as  
 attorney or agent and all powers derived therefrom shall terminate on the date such attorney or  
 agent ceases being so affiliated.


Schenk, Dale B.  
Application No.: 09/322,289  
Page 2

PATENT

Please continue to direct all communications to:

Joe Liebeschuetz  
Townsend and Townsend and Crew  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834

Respectfully submitted,



Joe Liebeschuetz  
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
Telephone: (650) 326-2400  
Facsimile: (650) 326-2422  
JOL:RLC

PA 3138155 v1